2020年10月26日 · Scorpion is a pioneering clinical-stage oncology company redefining the frontier of precision medicine to deliver transformational therapies for larger populations of patients with cancer

BOSTON, Mass. – November 7, 2022 – Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the formation of its Clinical Scientific Advisory Board (“Clinical SAB”).

Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer

At Scorpion Therapeutics, we are expanding the reach of precision medicine to more people with untreatable or treatment-resistant cancer.

Scorpion. Great culture and community, paired with our depth of knowledge, has created an atmosphere of creativity. Chemical Biologist. The power of perspectives. Our ability to make breakthrough impacts for patients starts with our people. We believe including people with diverse perspectives and experiences will enable us to develop ...

2023年10月13日 · Scorpion Therapeutics Accelerates Precision Oncology 2.0 for More Patient Populations. Read More

Scorpion Therapeutics, Inc., a pioneering clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, today announced the closing of a $150 million Series C financing.

BOSTON, MA. – January 7, 2021 – Scorpion Therapeutics, Inc., a next-generation precision oncology company, today announced the closing of an oversubscribed Series B financing, which raised $162 million.

Scorpion Therapeutics to Present STX-478 Initial Phase 1/2 Data at ESMO Congress 2024 BOSTON, Mass. – August 19, 2024 – Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, today announced that it ...

Address. 2 Tower Place 3rd Floor South San Francisco, Phone. 781-288-5760 . Contact us